Sign Up to like & get
recommendations!
0
Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000008009
Abstract: Rationale: Vanishing bile duct syndrome (VBDS) consists of a series of diseases characterized by the loss of >50% bile duct in portal areas. Many factors are associated with VBDS including infections, neoplasms, and drugs. Antibiotic…
read more here.
Keywords:
bile duct;
acute vanishing;
duct syndrome;
duct ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002505
Abstract: Vanishing bile duct syndrome (VBDS) is a condition resulting from progressive destruction and loss of intrahepatic bile ducts leading to cholestasis, biliary cirrhosis, and liver failure. It occurs secondary to various pathologic conditions like autoimmune…
read more here.
Keywords:
hodgkin lymphoma;
duct syndrome;
syndrome;
bile duct ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190019868358
Abstract: Background: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS),…
read more here.
Keywords:
efavirenz;
case;
bile duct;
efavirenz induced ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Internal medicine"
DOI: 10.2169/internalmedicine.1826-23
Abstract: Vanishing bile duct syndrome (VBDS) is a rare but potentially serious cholestatic liver disease caused by various etiologies, including drugs. We herein report a complicated case of VBDS with acute tubular necrosis (ATN) that improved…
read more here.
Keywords:
acute tubular;
tubular necrosis;
duct syndrome;
bile duct ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12020539
Abstract: Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report…
read more here.
Keywords:
bile duct;
combination therapy;
nivolumab cabozantinib;
therapy ... See more keywords